WO1997012909A1 - Nouvelles proteines membranaires d'helicobacter pylori - Google Patents
Nouvelles proteines membranaires d'helicobacter pylori Download PDFInfo
- Publication number
- WO1997012909A1 WO1997012909A1 PCT/FR1996/001552 FR9601552W WO9712909A1 WO 1997012909 A1 WO1997012909 A1 WO 1997012909A1 FR 9601552 W FR9601552 W FR 9601552W WO 9712909 A1 WO9712909 A1 WO 9712909A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- centrifugation
- recovered
- subjected
- nacl
- Prior art date
Links
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 6
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 6
- 108010052285 Membrane Proteins Proteins 0.000 title description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 122
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 122
- 239000012528 membrane Substances 0.000 claims abstract description 53
- 238000001962 electrophoresis Methods 0.000 claims abstract description 12
- 229920002401 polyacrylamide Polymers 0.000 claims abstract description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 107
- 239000000872 buffer Substances 0.000 claims description 64
- 239000011780 sodium chloride Substances 0.000 claims description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 238000005119 centrifugation Methods 0.000 claims description 44
- 239000008188 pellet Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 33
- 238000005406 washing Methods 0.000 claims description 23
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 22
- 230000001580 bacterial effect Effects 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- 241000589989 Helicobacter Species 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 15
- 238000005571 anion exchange chromatography Methods 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000012472 biological sample Substances 0.000 claims description 13
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 claims description 12
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 12
- 238000000527 sonication Methods 0.000 claims description 12
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 11
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 11
- 229920002684 Sepharose Polymers 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 102000016943 Muramidase Human genes 0.000 claims description 8
- 108010014251 Muramidase Proteins 0.000 claims description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 8
- 239000012614 Q-Sepharose Substances 0.000 claims description 8
- 239000012736 aqueous medium Substances 0.000 claims description 8
- 239000004325 lysozyme Substances 0.000 claims description 8
- 235000010335 lysozyme Nutrition 0.000 claims description 8
- 229960000274 lysozyme Drugs 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 238000005277 cation exchange chromatography Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000009432 framing Methods 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 description 42
- 239000000499 gel Substances 0.000 description 33
- 239000000427 antigen Substances 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 238000000746 purification Methods 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 102000016938 Catalase Human genes 0.000 description 10
- 108010053835 Catalase Proteins 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 102000018697 Membrane Proteins Human genes 0.000 description 9
- 108010046334 Urease Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 8
- 241000590017 Helicobacter felis Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010049048 Cholera Toxin Proteins 0.000 description 7
- 102000009016 Cholera Toxin Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 230000004520 agglutination Effects 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000006167 equilibration buffer Substances 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 101710176159 32 kDa protein Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010019375 Helicobacter infections Diseases 0.000 description 4
- 241000590006 Helicobacter mustelae Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000002051 biphasic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229940016590 sarkosyl Drugs 0.000 description 4
- 108700004121 sarkosyl Proteins 0.000 description 4
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 108010050327 trypticase-soy broth Proteins 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010090127 Periplasmic Proteins Proteins 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 108091005706 peripheral membrane proteins Proteins 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 108010006591 Apoenzymes Proteins 0.000 description 1
- DDBMKOCQWNFDBH-RHYQMDGZSA-N Arg-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O DDBMKOCQWNFDBH-RHYQMDGZSA-N 0.000 description 1
- QHBMKQWOIYJYMI-BYULHYEWSA-N Asn-Asn-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QHBMKQWOIYJYMI-BYULHYEWSA-N 0.000 description 1
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- KIAOPHMUNPPGEN-PEXQALLHSA-N Ile-Gly-His Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KIAOPHMUNPPGEN-PEXQALLHSA-N 0.000 description 1
- CNMOKANDJMLAIF-CIQUZCHMSA-N Ile-Thr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O CNMOKANDJMLAIF-CIQUZCHMSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GKFNXYMAMKJSKD-NHCYSSNCSA-N Lys-Asp-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GKFNXYMAMKJSKD-NHCYSSNCSA-N 0.000 description 1
- ODTZHNZPINULEU-KKUMJFAQSA-N Lys-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N ODTZHNZPINULEU-KKUMJFAQSA-N 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- WPTHAGXMYDRPFD-SRVKXCTJSA-N Met-Lys-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O WPTHAGXMYDRPFD-SRVKXCTJSA-N 0.000 description 1
- VWFHWJGVLVZVIS-QXEWZRGKSA-N Met-Val-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O VWFHWJGVLVZVIS-QXEWZRGKSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- 101001002763 Plasmodium chabaudi Acidic phosphoprotein Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- LPGSNRSLPHRNBW-AVGNSLFASA-N Pro-His-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 LPGSNRSLPHRNBW-AVGNSLFASA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- VEYXZZGMIBKXCN-UBHSHLNASA-N Trp-Asp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VEYXZZGMIBKXCN-UBHSHLNASA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- ZQGPWORGSNRQLN-NHCYSSNCSA-N Val-Asp-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ZQGPWORGSNRQLN-NHCYSSNCSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- -1 aluminum compound Chemical class 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002050 hydrofluoric acid Drugs 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to proteins of Helicobacter pylori newly obtained in substantially purified form, as well as the pharmaceutical compositions which contain them.
- Helicobacter is a bacterial genus characterized by gram negative spiral bacteria. Several species colonize the gastrointestinal tract of mammals. We cite in particular H. pylori, H. heilmanii, H. felis and H. mustelae. Although H. pylori is the species most commonly associated with human infections, in some cases certainly rare. H. heilmanii and H. felis have been isolated from humans.
- Helicobacter infects more than 50% of the adult population in developed countries and almost 100% of that of developing countries; making it one of the predominant infectious agents worldwide.
- H. pylori is found exclusively to date on the surface of the stomach lining in humans and more particularly around crater lesions of gastric and duodenal ulcers. This bacterium is currently recognized as the etiological agent of antral gastritis and appears as one of the cofactors required for the development of ulcers. Furthermore, it seems that the development of gastric carcinomas may be associated with the presence of H. pylori.
- H. proteins. pylori have been characterized or isolated to date. These include urease, composed of two subunits A and B of 30 and 67 kDa respectively ( ⁇ u & Mobley, Infect. Immun. (1990) 58: 992; Dunn et al, J. Biol. Chem .
- HpaA fibrillar hemaglutinin
- Hpn fibrillar hemaglutinin
- a 15 kDa protein rich in histidine Hpn
- a 30 kDa outer membrane protein Bolin et al, J. Clin. Microbiol. (1995) 33: 381
- a 20 kDa lipoprotein associated with the membrane Kostrcynska et al, J. Bact.
- urease is recognized as being a first choice antigen which can be used for this purpose (WO 94/9823; WO95 / 3824; WO 95/22987; Michetti et al, Gastroenterology (1994) 107: 1002).
- WO 94/9823 WO95 / 3824
- WO 95/22987 Michetti et al, Gastroenterology (1994) 107: 1002
- the subject of the invention is in particular an H. protein. pylori in substantially purified form, capable of being obtained from a membrane fraction of H. pylori, and whose molecular weight after electrophoresis on 10% polyacrylamide gel in the presence of SDS, appears to be of the order of 54, 50, 32-35 or 30 kDa.
- the protein has a molecular weight of approximately 54 kDa, it is further specified that it does not react with an anti-catalase antiserum.
- H. catalase antiserum. pylori can in particular be prepared according to the immunization method described in Example 5 below, using a catalase preparation obtained by chromatography. as described in Example 6.
- substantially purified form is meant that the protein is separated from the environment in which it exists naturally. Among others, it may be a preparation in particular devoid of the cytoplasmic and periplasmic proteins of H. pylori. d -
- the membrane protein whose apparent molecular weight is of the order of 54 kDa can be obtained by a process in which:
- a bacterial pellet is recovered which is treated with lysozyme and which is subjected to sonication, followed by centrifugation;
- the membrane fraction is subjected to anion exchange chromatography on a Q-Sepharose column in a 0-1.5 M NaCl gradient, advantageously in a carbonate buffer p ⁇ 9.5 to 0.1% of zwittergent 3-14 , followed by washing with 1 M NaCl, advantageously in a carbonate buffer p ⁇ 9.5 to 0.1% of zwittergent 3-14;
- the membrane protein whose apparent molecular weight is of the order of 50 kDa can be obtained by a process in which:
- the membrane fraction is subjected to anion exchange chromatography on a Q-Sepharose column in 0 - 0.5 M NaCl gradient, advantageously in a carbonate buffer pH 9.5 at 0.1% of zwittergent 3-14 , followed by washing with 1 M NaCl, advantageously in a carbonate buffer pH 9.5 at 0.1% of zwittergent 3-14;
- the membrane protein whose apparent molecular weight is of the order of 30 kD can be obtained by a process in which:
- the membrane fraction is subjected to anion exchange chromatography on a Q-Sepharose column in a 0-1.5M NaCl gradient, advantageously in a carbonate buffer pH 9.5 at 0.1% of zwittergent 3-14;
- the membrane protein whose apparent molecular weight is of the order of 32-35 kDa is capable of being obtained by a process in which:
- a bacterial pellet is recovered which is treated with lysozyme and which is subjected to sonication, followed by centrifugation;
- the membrane fraction consisting of the centrifugation pellet is recovered which is resuspended in an aqueous medium, advantageously in carbonate buffer pH 9.5;
- the suspension obtained in (iv) is centrifuged at approximately 200,000 xg and the supernatant is recovered;
- the preparation obtained in (vi) is subjected to a cation exchange chromatography on a column of SP-Sepharose in 0-1.5 M NaCl gradient, advantageously in a pH 7 phosphate buffer;
- the proteins of 54, 50, 32 and 30 kDa according to the invention are probably intrinsic membrane proteins or proteins associated with the membrane.
- the 54 kDa protein does not react with anti-catalase antibodies, neither in western blot nor in dot blot.
- the 30 kDa protein does not react with antibodies against the urease A subunit, neither in western blot nor in dot blot.
- the 32 kDa protein turns out to be an alkaline protein; its molecular weight may appear slightly higher e.g. of the order of 35 kDa under certain experimental conditions.
- N-terminal sequence of the 50 kDa protein of an H. strain. pylori is as follows (one letter code): MKEKFNRTKP ⁇ VNIGTIG ⁇ VD ⁇ .
- This information does not exclude the fact that equivalent proteins capable of being purified according to the process indicated above may have a slightly different N-terminal sequence, insofar as they are derived from another bacterial strain. Such a difference would indeed reflect the phenomenon of allelic variance commonly encountered within the same species. For example, a bacterial species is usually represented by a set of strains which differ from each other by minor allelic characteristics. A polypeptide that performs the same biological function in different strains may have an amino acid sequence that is not the same for all strains. Such an allelic variation is also found at the DNA level.
- allelic differences in the amino acid sequence may consist of one or more substitutions, deletions or additions of amino acids, which do not alter the biological function.
- biological function is meant the function of the protein which participates in the survival of cells in which the protein exists naturally (even if the function is not absolutely essential).
- the function of a porine is to allow compounds present in the external environment to enter the interior of the cell.
- the biological function is distinct from the antigenic function.
- a protein can have more than one biological function.
- the subject of the invention is also a protein in substantially purified form and capable of having been purified according to one of the methods described above from a bacterium of the genus Helicobacter eg, H. pylori, H heilmanii, H. felis and H. mustelae.
- the subject of the invention is also any other protein or polypeptide, in substantially purified form, insofar as it is analogous in terms of antigenicity to a Helicobacter protein capable of being purified according to one of the methods described above.
- polypeptides these are in particular polypeptides derived by fragmentation or by mutation of one or more amino acids, e.g. by deletion. addition or substitution of a protein which exists in nature and whose purified form can be obtained according to one of the methods described above.
- Such polypeptides can in particular be obtained by enzymatic digestion using proteases such as pepsin or trypsin. It is not necessary that such polypeptides can be purified by one of the methods described above.
- polypeptide is reserved to denote a product derived from a protein by fragmentation or mutation.
- a protein or polypeptide according to the invention must be capable of being recognized by monospecific antibodies established against a Helicobacter protein capable of being purified according to one of the methods described above. This specific antigenicity can be revealed by a number of methods; for example by
- the product intended to be tested eg either in the form of a purified preparation, or in the form of a bacterial extract, is subjected to an electrophoresis in SDS gel Page (10% polyacrylamide) as described by Laemmli UK, Nature (1970) 227: 680. After transfer to a nitrocellulose membrane, the latter is incubated with a monospecific hyperimmune serum diluted in the range of dilutions from 1: 50 to 1 : 5000, preferably from 1: 100 to 1: 500. The specific antigenicity is demonstrated as soon as a band corresponding to the product tested exhibits reactivity to one of the dilutions included in the range established above.
- the product to be tested is preferably used to cover the wells. It is preferred to use a purified preparation, although a total extract may also be used.
- 100 ⁇ l of a preparation at 10 ⁇ g of protein / ml are distributed in the wells of a 96-well plate. The plate is incubated for 2 hrs at 37 ° C. and then overnight at 4 ° C. The plate is washed with PBS buffer (phosphate buffered saline) containing 0.05% Tween 20 (PBS / Tween buffer). The wells are saturated with 250 ⁇ l of PBS containing 1% bovine serum albumin (BSA).
- BSA bovine serum albumin
- the medium is incubated for 1 hour at 37 ° C., then the plate is washed with PBS / Tween buffer.
- a monospecific rabbit antiserum is serially diluted in PBS / Tween buffer containing 0.5% BSA.
- One hundred ⁇ l of a dilution is added to each well.
- the plate is incubated for 90 min at 37 ° C. and then washed.
- the plate is revealed according to standard methods. For example, a rabbit anti-immunoglobulin goat peroxidase-immunoglobulin conjugate is added to the wells.
- the incubation is continued for 90 min at 37 ° C., then the plate is washed.
- the reaction is developed with the appropriate substrate.
- the reaction is measured by colorimetry (absorbance measured by spectrophotometry). Under these conditions, a positive reaction is observed when an OD value of 1 is associated with a dilution of at least 1:50, preferably at least 1: 500.
- the appropriate wavelength at which the optical density depends on the substrate.
- a preparation of the product to be tested with 100 ⁇ g of protein / ml is diluted in series twice in 50 mM Tris-HCl pH 7.5.
- 50 mM Tris-HCl pH 7.5 One hundred ⁇ l of each dilution is applied to a 0.45 ⁇ m nitrocellulose membrane in a 96-well dot blot device (Biorad).
- the buffer is removed by vacuum.
- the wells are washed by adding 50 mM Tris-HCl pH 7.5 and the membrane is air dried.
- the membrane is saturated with blocking buffer (50 mM Tris-HCl pH 7.5, 0.15 M NaCl, skimmed milk 10 g / 1) then incubated with a monospecific antiserum diluted in the range of 1: 50 to 1: 5000. preferably 1: 50 to 1: 500.
- the reaction is revealed according to standard methods. For example, a goat peroxidase-immunoglobulin conjugate rabbit anti-immunoglobulin is added to the wells. Incubation is continued 90 min at 37 ° C then the plate is washed. The reaction is developed with the appropriate substrate. The reaction is measured by colorimetry or chemiluminescence.
- a reaction is positive when a coloration is observed at the level of the deposition on the nitrocellulose sheet directly for revelation by colorimetry or on photographic film for revelation by chemiluminescence, associated with a dilution of at least 1:50, preferably at least 1: 500.
- a protein according to the invention can in particular be obtained by purification from Helicobacter or expressed by recombinant way in a heterologous system (which can also be the case for a polypeptide according to the invention).
- the protein may have post-translational modifications which are not identical to those of the corresponding protein derived from the original strain.
- the therapeutic or prophylactic efficacy of a protein or a polypeptide according to the invention can be evaluated according to standard methods; for example by measuring the induction of a mucosal immune response or the induction of an immune response with a therapeutic or protective effect using e.g. the mouse / H. felis model and the procedures described in Lee et al, Eur. J. Gastroenterology & ⁇ epatology, (1995) 7: 303 or Lee et al, J. Infect. Say. (1995) 172: 161, provided that the following precaution is taken: When the protein originates from a species other than H. felis, the strain of H.
- felis must be replaced by a strain of Helicobacter belonging to the species from which the protein originates and adapted for this purpose (the other experimental conditions remaining identical).
- a strain of H. pylori to induce a protective or therapeutic effect, by substituting a strain of H. pylori.
- Such a strain is proposed by e.g. Kleanthous et al. Abstr. presented at the VlIIth International Workshop on Gastroduodenal Pathology 7-9th July 1995, Edinburgh, Scotland.
- a protective effect is noted when an infection in the gastric tissue is less compared to a control group. Infection is assessed by testing urease activity, bacterial load or leukocyte infiltration. For example, when a reduction in urease activity in the gastric tissue is found after the test, even if it is not completely abolished, it is fair to say that there is partial protection.
- the invention also relates to (i) a composition of matter comprising a protein or a polypeptide according to the invention and a diluent or a support; in particular (ii) a pharmaceutical composition, in particular intended for the prevention or treatment of a Helicobacter infection.
- a protein or polypeptide according to the invention which includes as active ingredient a protein or polypeptide according to the invention, in an amount effective from a prophylactic or therapeutic point of view; (iii) the use of a protein or a polypeptide according to the invention as a therapeutic or prophylactic agent; (iv) the use of a protein or a polypeptide according to the invention for the manufacture of a medicament intended for the prevention or the treatment of a Helicobacter infection; as well as (v) a method of inducing an immune response against Helicobacter eg, H. pylori, H. heilmanii, H. felis and H.
- a mammal according to which said mammal is administered a quantity immunologically effective of a protein or polypeptide according to the invention in order to develop an immune response; in particular (vi) a method of preventing or treating a Helicobacterlle infection, an individual is administered a prophylactically or therapeutically effective amount of a protein or a polypeptide according to the invention.
- the methods and pharmaceutical compositions according to the invention can treat or prevent infections with Helicobacter and consequently, the gastrointestinal diseases associated with such infections.
- infections include, in particular, acute chronic atrophic gastritis; peptic ulcers e.g. gastric and duodenal ulcers; gastric cancers; chronic hyperopia; refractory non-ulcerative dyspepsia; intestinal metaplasia and certain lymphomas (e.g. low grade MALT lymphoma).
- a composition according to the invention can be administered by any conventional route in use in the field of vaccines, in particular through a mucosal surface (eg ocular, nasal, oral, gastric, intestinal, rectal, vaginal, or urinary tract) or parenterally (eg subcutaneous, intradermal, intramuscular, intravenous, or intraperitoneal).
- a mucosal surface eg ocular, nasal, oral, gastric, intestinal, rectal, vaginal, or urinary tract
- parenterally eg subcutaneous, intradermal, intramuscular, intravenous, or intraperitoneal.
- the choice of administration route depends on a certain number of parameters such as the adjuvant associated with the protein or the polypeptide according to the invention. For example, if a mucosal adjuvant is used, the nasal or oral route is preferred. If a lipid formulation is used, the parenteral route will be chosen, preferably the subcutaneous or intramuscular route.
- a composition according to the invention can comprise, in addition to a protein or a polypeptide according to the invention, at least one other Helicobacter antigen such as the urease apoenzyme. or a subunit, fragment, homolog, mutant or derivative of this urease.
- a protein or a polypeptide according to the invention can be formulated in or with liposomes, preferably neutral or anionic liposomes, microspheres. ISCOMs or viral pseudo-particles (VLPs), to promote targeting of the protein or polypeptide or to increase the immune response.
- liposomes preferably neutral or anionic liposomes, microspheres.
- ISCOMs or viral pseudo-particles (VLPs) to promote targeting of the protein or polypeptide or to increase the immune response.
- Adjuvants other than liposomes can also be used. Many are known to those skilled in the art. Such adjuvants are referenced below:
- aluminum compounds such as aluminum hydroxide, aluminum phosphate and aluminum hydroxyphosphate are mentioned.
- the antigen can be adsorbed or precipitated on an aluminum compound according to standard methods.
- Other adjuvants such as RIBI from ImmunoChem (Hamilton, MT) can be used for parenteral administration.
- bacterial toxins e.g. cholera toxin (CT), toxin from E. coli. heat labile coli (LT) Clostridium difficile toxin and pertussis toxin (PT) as well as the detoxified forms (subunit, toxoid or mutant) of these toxins.
- CT cholera toxin
- LT heat labile coli
- PT pertussis toxin
- a preparation containing the CT subunit B (CTB) and a smaller amount of CT can be used.
- Fragments, homologs and derivatives of these toxins are likewise suitable insofar as they retain an adjuvant activity.
- a mutant having reduced toxicity is used.
- Such mutants are described eg in WO 95/17211 (Arg-7-Lys CT mutant), WO 95/34323 (Arg-9-Lys Glu-129-Gly PT mutant) and WO 96/6627 (Arg-192-Gly Mutant LT).
- Other adjuvants such as the major bacterial lipopolysaccharide (MPLA) of e.g. E. coli, Salmonella minnesota, Salmonella typhimurium or Shigella flexneri, can be used for mucosal administration.
- MPLA major bacterial lipopolysaccharide
- Adjuvants useful for both mucosal and parenteral administration include in particular polyphosphazene (WO 95/2415).
- DC-chol (3 betâ- [N- (N'.N'-dimethyl aminomethane) -carbamoyl] cholesterol) (USP 5,283,185 and WO 96/14831) and QS-21 (WO 88/9336).
- the administration can take place in single or repeated dose one or more times after a certain delay.
- the appropriate dosage varies depending on various parameters, for example. of the individual treated (adult or child) of the vaccine antigen itself of the mode and frequency of administration, of the presence or absence of adjuvant and if present, of the type of adjuvant and of the effect desired (eg protection or treatment), as can be determined by those skilled in the art.
- an antigen according to the invention can be administered in an amount ranging from 10 ⁇ g to 500 mg, preferably from 1 mg to 200 mg.
- a parenteral dose should not exceed 1 mg, preferably 100 ⁇ g. Higher doses may be prescribed for eg oral use.
- the amount of protein administered to humans by the oral route is, for example, of the order of 1 to 10 mg per dose, and at least 3 doses are recommended at 4-week intervals.
- a composition according to the invention can be produced in a conventional manner.
- a protein or a polypeptide according to the invention is combined with a diluent or a support which is acceptable from a pharmaceutical point of view, eg water or a saline solution such as a phosphate salt buffer (PBS), supplemented. optionally with a bicarbonate salt such as sodium bicarbonate eg 0.1 to 0.5 M when the composition is intended for oral or intragastric administration.
- a diluent or carrier is selected based on the mode and route of administration and standard pharmaceutical practices. Pharmaceutically acceptable diluents and carriers and all that is necessary for their use in pharmaceutical formulations are described in Remington's Pharmaceutical Sciences, a standard reference text in this area and in the USP / NP.
- a protein or a polypeptide according to the invention can be encapsulated alone or in the presence of other H. pylori proteins in gelatin capsules in order to protect the antigen against degradation by gastric juice or else administered in presence of sodium bicarbonate.
- Such formulations have already been used for pharmaceutical compositions (Black et al. Dev. Biol. Stand. (1983) 5_3: 9).
- the protein can also be encapsulated in microspheres of
- PLGA copolymers of glycolic acid and lactic acid
- a protein or polypeptide according to the invention can be administered parenterally. To do this, a protein or polypeptide according to the invention is adsorbed on alumina gel in a completely conventional manner.
- the protein in solution at 1 mg / ml in a buffer whose pH is close to 6.5 is contacted for 1 hour with aluminum hydroxide at 10 mg / ml measured at AL " 1-1" 1 " .
- the final composition of the preparation is as follows: protein 50 ⁇ g / ml, AL +++ 250 ⁇ g / ml, merthiolate 1 / 10,000, all in PBS. As in the case of oral administration, 3 injections are recommended each spaced 4 weeks from the previous one.
- a polypeptide according to the invention can also be useful as a diagnostic reagent, for example for detecting the presence of anti-Helicobacter antibodies in a biological sample e.g. a blood sample.
- a polypeptide advantageously comprises 5 to 80 amino acids, preferably 10 to 50 amino acids.
- a polypeptide reagent according to the invention may or may not be labeled. according to the diagnostic method used. Diagnostic methods are described further in the text.
- the invention provides a monospecific antibody capable of recognizing a protein or a polypeptide according to the invention.
- an antibody capable of reacting mainly with a single Helicobacter protein. Such an antibody can only be obtained by using a substantially purified protein, as an immunogen.
- An antibody according to the invention can be polyclonal or monoclonal; the monoclonals can be chimeric (for example, constituted by a variable region of murine origin associated with a constant human region) or humanized (only the hypervariable regions are of animal origin, for example of murine origin) and / or by a single chain.
- the polyclonal as the monoclonal can also be in the form of fragments of immunoglobulins for example a fragment F (ab) '2 or Fab.
- An antibody according to the invention can also be of any isotype, for example IgG or IgA; a polyclonal can be of a single isotype or a mixture of all or part of them.
- An antibody which is directed against a protein according to the invention can be produced and subsequently identified using a standard immunoassay, for example Western blot, dot blot or ELISA analysis (see for example Coligan et al, Current Protocols in Immunology (1994) John Wiley & sons Inc., New York, NY); Antibodies: A laboratory Manual, D. Lane, (1988) Harlow Ed.).
- a standard immunoassay for example Western blot, dot blot or ELISA analysis (see for example Coligan et al, Current Protocols in Immunology (1994) John Wiley & sons Inc., New York, NY); Antibodies: A laboratory Manual, D. Lane, (1988) Harlow Ed.).
- An antibody according to the invention can be useful in diagnosis, as well as in affinity chromatography for purifying on a large scale, a protein or a polypeptide according to the invention; such an antibody is also potentially useful as a therapeutic agent in a passive immunization procedure.
- the invention also provides (i) a reagent for detecting the presence of Helicobacter in a biological sample, which comprises an antibody or a polypeptide according to the invention; and (ii) a diagnostic method for detecting the presence of Helicobacter in a biological sample, according to which the biological sample is brought into contact with an antibody or a polypeptide according to the invention, so that an immune complex is formed; optionally, the unbound material is eliminated. and detecting the immune complex formed between the sample and the antibody or the polypeptide according to the invention, as an indicator of the presence of Helicobacter in the sample or in the organ in which the sample has been collected.
- an antibody according to the invention makes it possible to test the presence of Helicobacter in a gastric extract.
- the reagent to be presented in free form or immobilized on a solid support can be any support commonly used in this field, for example, a tube, a ball or a well.
- Immobilization can be obtained by direct or indirect means.
- the direct means include passive adsorption (non-covalent bond) or covalent bonds between the support and the reagent.
- indirect means it is meant that an anti-reagent compound capable of interacting a reagent is first of all attached to a solid support. For example, if you use a polyvinyl reagent.
- an antibody capable of binding it can be used as an anti-reagent, provided that it can bind to an epitope of the polypeptide which is not involved in the recognition of the antibodies present in the biological samples.
- the indirect means can also be implemented via a ligand-receptor system. for example by grafting a molecule, such as a vitamin, onto a polypeptide reagent and then immobilizing the corresponding receptor in solid form. This is illustrated eg by the biotin-streptavidin system.
- we use indirect means for example by adding a peptide tail to the reagent eg by chemical means, and by immobilizing the grafted product by passive adsorption or by covalent bonding of the peptide tail.
- the invention also relates to a method for purifying a protein or a polypeptide according to the invention from a biological sample, according to which the biological sample is subjected to an affinity chromatography using a monospecific antibody according to the invention.
- the antibody can be polyclonal or monoclonal, preferably of the type
- IgG IgG. Purified IgGs can be prepared from an antiserum according to commonly practiced methods (see for example Coligan et al).
- a biological sample preferably in a buffer solution
- chromatography equipment preferably equilibrated with the buffer used for diluting the biological sample so that the protein or the polypeptide according to the invention (antigen ) can be adsorbed on the material.
- Chromatography equipment such as a gel or a resin associated with an antibody according to the invention, can be in the form of a bath or a column.
- the components which remain unbound are eliminated by washing and the antigen is then eluted in an appropriate elution buffer, such as for example, a glycine buffer or a buffer containing a chaotropic agent eg guanidine HCl, or a rich concentration. salt (for example, 3M MgCl 2 ).
- the eluted fractions are recovered and the presence of the antigen is then demonstrated, for example by measuring the absorbance at 280 nm.
- Such a purification process can, for example, be used to purify a protein from a total extract.
- the material intended to be subjected to immunoaffinity chromatography should first be enriched. in quantity of protein to be purified.
- such a method can be used to perfect the purification of the 32 kDa protein as obtained according to the method described above comprising a purification step on SP-Sepharose.
- the therapeutic or prophylactic utility of an antibody according to the invention can be demonstrated according to the protection test of Lee et al. proposed above for the proteins or polypeptides according to the invention.
- the subject of the invention also also is (i) a composition of matter comprising a monospecific antibody according to the invention, and a diluent or a support; in particular, (ii) a pharmaceutical composition comprising a monospecific antibody according to the invention in an amount effective from a therapeutic or prophylactic point of view; (iii) the use of a monospecific antibody according to the invention in the preparation of a medicament for treating or preventing a Helicobacter infection; as well as (iv) a method for treating or preventing a Helicobacter infection (eg H. pylori. H. felis, H. mustelae or H. heilmanii), according to which a therapeutically or prophylactically effective amount of an antibody is administered according to the invention, to an individual in need of such treatment.
- a Helicobacter infection eg H. pylori. H. felis, H. mustelae or H. heilmanii
- the monospecific antibody can be polyclonal or monoclonal, preferably of the IgA isotype (predominantly).
- the antibody is administered mucosally to a mammal, for example in the gastric mucosa, either orally or intragastrically, advantageously in the presence of a bicarbonate buffer.
- a monospecific antibody according to the invention can be administered as the sole active component or as a mixture comprising at least one monospecific antibody specific to each Helicobacter polypeptide.
- the dose of antibody to be used in this method can be readily determined by those of skill in the art. For example, it is indicated that a dosage can be characterized by a daily administration of between 100 and 1000 mg of antibody for one week; or a dose comprising 100 to 1000 mg of antibody administered three times a day for two to three days.
- a pharmaceutical composition comprising an antibody according to the invention can be produced according to the rules set out above for a composition comprising a protein or a polypeptide according to the invention. Likewise, identical medical indications apply.
- FIG 1 is a summary diagram of the protocol for preparing the membrane fractions I. II and III of H. pylori.
- Figure 2 presents the analysis of the membrane fractions I. II and III by electrophoresis on 10% polyacrylamide gel and staining with Coomassie blue. The samples deposited are: the membrane fraction I (column 2), the membrane fraction II (column 3), the membrane fraction III (column 4) and the molecular weight markers (column 1).
- Figure 3 presents the analysis by electrophoresis on 10% polyacrylamide gel and staining with Coomassie blue, proteins purified from a preparative gel (columns 3 to 7).
- the samples deposited are: the HpP1 fraction (column 3), the HpP2 fraction (column 4), the HpP4 fraction (column 5), the HpP5 fraction (column 6), the HpP6 fraction (column 7), the molecular weight markers (columns 1 and 8) and the membrane fraction I (column 2).
- Figure 4 presents the analysis of the fractions resulting from the passage on DEAE Sepharose, fractions 7 and 9 (obtained after elution on Q Sepharose). The fractions were separated by electrophoresis on 10% or 12.5% polyacrylamide gel and stained with Coomassie blue. The samples deposited are: fraction 7 (column 2A). fraction 7.1 (column 3 A), fraction 7.2 (column 4A), fraction 9 (column 2B). fraction 9.1 (column 3B), fraction 9.2 (column 4B). fraction 9.3 (column 5B) and the molecular weight markers (kDa) (column 1 A and IB).
- FIG. 5 shows, after electrophoresis on 10% polyacrylamide gel and staining with Coomassie blue, the electrophoretic profile of fraction D resulting from chromatography on a Q-Sepharose column of the membrane fraction III (column 3) and of the fraction From chromatography on column of S-Sepharose of fraction D (column 4).
- Column 1 corresponds to the molecular weight markers and column 2 to the membrane fraction III.
- the H. pylori ATCC 43579 strain is cultured in a liquid medium in a 10 L fermenter.
- a freezer of germs in glycerol is used to inoculate a 75 cm ⁇ bottle containing medium called "biphasic" (a solid phase in Colombia agar containing 6% fresh sheep blood and a liquid phase in soy trypticase containing 20% fetal calf serum).
- the liquid phase of this culture is used to inoculate several 75 cm 3 flasks in a biphasic medium in the absence of sheep blood.
- the liquid phase makes it possible to inoculate a biofermenter of 2 1 in a soy trypticase liquid medium containing beta cyclodextrin at 10 g / 1.
- This culture at OD 1.5-1.8 is inoculated in a 10 L fermenter in liquid medium. After 24 hours of culture, the bacteria are harvested by centrifugation at 4000 x g for 30 minutes at 4 ° C. A culture of 10 liters of H. pylori ATCC 43579 in a fermenter makes it possible to obtain approximately 20 to 30 g (wet weight) of bacteria.
- the pellet of germs obtained previously is washed with 500 ml of PBS (phosphate buffered saline; NaCl 7.650 g, disodium phosphate 0.724 g monopotassium phosphate 0.210 g for one liter; p ⁇ 7.2) per liter of culture. Then the germs are again centrifuged under the same conditions.
- PBS phosphate buffered saline
- NaCl 7.650 g disodium phosphate 0.724 g monopotassium phosphate 0.210 g for one liter; p ⁇ 7.2
- the bacterial pellet obtained (Cj) is resuspended in a 1% solution of OG (Sigma) (30 ml / liter of culture). The bacterial suspension is incubated for
- the pellet (C2) is kept for further processing.
- the precipitate formed during dialysis is recovered by centrifugation at 2
- the pellet (C2) obtained after centrifugation of the germs treated with the OG is resuspended in 20 mM Tris-HCl buffer pH 7.5 and 100 ⁇ M Pefabloc (buffer
- the procedure can be continued by a double washing of the C4 pellet to remove the peripheral membrane proteins.
- the C4 pellet is resuspended in 50 mM NaC03 buffer pH 9.5, Pefabloc and 100 ⁇ M (buffer B).
- the suspension is ultracentrifuged at 210,000 x g for 30 minutes at 4 ° C.
- the supernatant (S5) is eliminated then the pellet (C5) is washed and ultracentrifuged under the same conditions as above.
- the pellet (C ⁇ ) which essentially contains intrinsic membrane proteins, is stored at -20 ° C.
- fractions C4, C6 and C ⁇ 2d are hereinafter called membrane fractions I, II and III respectively.
- the profile of the membrane fraction I shows 7 major protein bands of respective molecular weights 87. 76, 67, 54, 50, 47 and 32-35 kDa (column 2).
- the band at 67 kDa corresponded to the B subunit of urease and the band at 54 kD corresponded to catalase.
- These two proteins are not found in the profile of fraction II (column 3) since washing in carbonate buffer eliminates the proteins weakly associated with the membrane.
- the protein profile of the membrane fraction III shows the presence of 4 major bands at 76, 67, 50 and 30 kDa (column 4).
- Electrophoresis is carried out on polyacrylamide gel according to the method of Laemmli (1970) with a gel of concentration of 5% and a separation gel of 10%.
- the membrane fraction is resuspended in buffer A, then diluted to half in the 2X sample buffer. The mixture is heated for 5 minutes to 95 ° C. About 19 mg of protein are deposited on a gel of dimension 16 x 12 cm and thickness 5 mm. Premigration is carried out at 50 V for 2 hours, followed by migration at 65 V overnight.
- the coloring of the gel with Coomassie R250 blue (0.05% in ultrafiltered water) allows good visualization of the bands.
- PMSF phenyl methyl sulfonyl fluoric acid
- Each pellet is taken up in 2 ml of 10 mM NaP04 solubilization buffer pH 7.0, 1 M Sarkosyl 0.1% NaCl, 100 ⁇ M PMSF, 100 ⁇ M Pefabloc and 6 M urea (buffer D).
- the solubilized sample is dialyzed successively against 100 ml of buffer D with 4 M urea and 0.1% of Sarkosyl, against 100 ml of buffer D with 2 M of urea and 0.5% of Sarkosyl and against 2 times 100 ml of buffer D without urea and 0.5% Sarkosyl. Dialysis is carried out for 1 hour with magnetic stirring at room temperature.
- the final dialysate is incubated for 30 minutes in an ice bath, then centrifuged at low speed for 10 minutes at 4 ° C (Biofuge A, Heraeus Sepatech). The supernatant is recovered, filtered on a Millipore filter at 0.45 ⁇ m and stored at -20 ° C.
- HpP1, HpP2 and HpP4 fractions are pure with a single band on gel for each of these fractions (at 87, 76 and 54 kDa respectively).
- the HpP5 fraction presents a high intensity band at 50 kDa slightly contaminated by a band at 47 kDa; similarly, the HpP6 fraction presents a high intensity band at 32 kDa slightly contaminated by a band at 35 kDa.
- the equilibration buffer NaCO ⁇ 50 mM pH 9.5, Pefabloc lOO ⁇ M and Zwittergent 3-14 0.1%) until absorbance at 280 nm is stabilized.
- Proteins are eluted by a gradient of 0.1 to 0.5 M NaCl in the equilibrium buffer (10 times V d ), followed by washing in equilibration buffer containing 0.5 and 1 M NaCl (2 times Vj).
- the collected fractions are analyzed by SDS-PAGE and pooled into different pools according to their electrophoretic profile, then stored at -20 ° C.
- the fractions are as follows:
- the protein balance shows that 53% of the proteins are eluted during the 0-0.5 M NaCl gradient. 14% of the proteins are not fixed on the column and 33% of the proteins are eluted during the NaCl 1 washing. M (Table 5). The proteins not fixed on the column, correspond to alkaline proteins positively charged at pH 7.5, while the proteins eluted in 1 M NaCl correspond to acid proteins highly charged at this pH.
- the column is washed, then equilibrated with the 50 mM Tris-HCl buffer pH 7.5, Pefabloc 100 ⁇ M and 0.1% Zwittergent 3-14.
- the chromatography is followed as above by UV detection at 280 nm at the outlet of the column. Fraction 7 dialyzed beforehand against the balancing buffer (Tris-HCl 50 mM pH 7.5.
- Pefabloc 100 ⁇ M and Zwittergent 3-14 0.1%) containing 10 mg of proteins is deposited on the DEAE Sepharose column.
- the column is washed in equilibration buffer until the absorbance at 280 nm is stabilized.
- the proteins are eluted by a gradient from 0 to 0.5 M NaCl in the equilibration buffer (10 times Vj), followed by washing with equilibration buffer containing 1 M NaCl (2 times x Vr).
- the collected fractions are analyzed by SDS-PAGE, then collected in different pools according to their protein profile and stored at -20 ° C. By SDS-PAGE, we show that fraction 7.1 (direct eluate) is of interest.
- fraction 9 containing 31 mg of proteins.
- SDS-PAGE SDS-PAGE it is shown that the fractions 9.1, 9.2 and 9.3 respectively eluted at 0.1 -0.25 M NaCl, 0.3 -0.4 M NaCl and 1 M NaCl are of interest.
- the membrane fraction I is dissolved in 50 mM NaC ⁇ 3 buffer pH 9.5 at room temperature for 30 min with stirring. The suspension is then centrifuged at 200,000 xg for 30 min at + 4 ° C. The supernatant is dialyzed against 50 mM NaPO 4 buffer pH 7.0 and then deposited on a column of SP-Sepharose previously equilibrated with this same buffer. After washing the column with the same buffer, the column is subjected to a 0-0.5 M NaCl gradient. The fraction eluted between 0.26 and 0.31 M contains the protein of 32 kDa. EXAMPLE 5 Preparation of hyperimmune sera against the HpP5 and HpP6 fractions.
- the anti-HpP5 antiserum reacts with the protein of 50 kDa isolated in fraction 9.2 obtained in Example 3.
- the anti-HpP6 antiserum reacts with the protein of 32 kDa isolated in the fraction eluted between 0.26-0, 31 M NaCl on SP-Sepharose, as obtained in Example 4.
- the immunization protocol described above can be used in a similar manner to produce antisera against each of the proteins purified in Example 3.
- the preparations obtained in these examples may advantageously be subjected to electrophoresis preparative on SDS-PAGE gel.
- the protein bands will be treated as above in order to obtain a preparation intended for immunization.
- Example IA A culture is carried out as described in Example IA.
- the washed bacterial pellet is resuspended in 50 mM sodium phosphate buffer p ⁇ 7.5 containing PMSF (phenvlmethylsulfonyl fluoride Sigma) 100 ⁇ M (buffer A) at a final concentration of 0.1 g (wet weight) per milliliter.
- the suspension is homogenized using an Ultraturrax type mixer.
- the bacterial cells are then broken by sonication with a device of the Sonifier type (Branson) equipped with a probe with a diameter of 1.8 cm. Sonication is done intermittently. 1 min of sonication and 1 min of rest on ice. A 10 min sonication is enough to completely break 5 g of suspended germs.
- the lysate thus obtained is centrifuged for 15 min at 4 ° C at 4,000 g.
- the supernatant is recovered then centrifuged again at 100,000 g for 30 min at 4 ° C.
- the supernatant from this second centrifugation (S2) is recovered for chromatographic purification.
- the S2 fraction prepared in this way retains about 90% of the total "catalase” enzymatic activity, as measured according to the technique of Hazell et al (supra) or Beers & Sizer. J. Biol. Chem. (1952) 195: 133.
- the fraction S2 is loaded onto an S-Sepharose column (Pharmacia) previously equilibrated with buffer A.
- the column is washed with the same buffer.
- the chromatography is followed with a UV detector at 280 nm for the proteins and by the enzymatic activity for the catalase. After elimination of the non-fixed proteins (the absorption at 280 nm returns to the baseline), the column is then washed with a NaCl gradient, 0 to IM in buffer A.
- the fractions corresponding to the peak of the activity catalase are collected, concentrated in an Amicon-type concentration cell equipped with a membrane, the cutoff threshold of which is 100,000 Daltons.
- the concentrated fraction thus obtained is loaded onto a Sephacryl S-300 HR column previously equilibrated with PBS buffer.
- the fractions containing catalase activity are collected, concentrated to 1 mg / ml and dialyzed against the PBS buffer.
- the final solution is filtered through a membrane with a porosity of 0.22 ⁇ m and stored at -70 ° C.
- Example 5 An anti-HpP5 anti-fraction serum as prepared in Example 5 is deposited on a Protein A Sepharose 4 Flast Flow column (Pharmacia) previously balanced in 100 mM Tris-HCl pH 8.0. The resin is washed with 10 column volumes of 100 mM Tris-HCl pH 8.0 and then with 10 column volumes of
- IgGs 10 mM Tris-HCl pH 8.0.
- IgGs are eluted in 0.1 M pH 3.0 glycine buffer.
- the IgGs are collected as 5 ml fractions to which 0.25 ml of 1 M Tris-HCl pH 8.0 is added.
- the optical density of the eluate is measured at 280 nm and the fractions containing the IgGs are combined and if necessary, frozen at -70 ° C.
- CNBr - activated Sepharose 4B gel (knowing that 1 g of dry gel gives approximately 3.5 ml of hydrated gel and that the capacity of the gel is 5 to 10 mg of IgG per ml of gel) manufactured by Pharmacia ( ref: 17-0430-01) is suspended in 1 mM NaCl buffer. The gel is then washed using a buchner by adding small amounts of 1 mM HCl. The total volume of 1 mM HCl used is 200 ml per gram of gel.
- the purified IgGs are dialyzed for 4 hrs at 20 + 5 ° C against 50 vol. 500 mM sodium phosphate buffer pH 7.5. They are then diluted in 500 mM sodium phosphate buffer pH 7.5 to a final concentration of 3 mg / ml.
- the IgGs are incubated with the gel overnight at 5 + 3 ° C with rotary shaking.
- the gel is placed in a chromatography column and washed with 2 vol. column of 500 mM phosphate buffer pH 7.5.
- the gel is then transferred to a tube and incubated in 100 mM ethanolamine pH 7.5 at room temperature with stirring. It is then washed by 2 vol. PBS column.
- the gel can be stored in PBS merthiolate 1 / 10,000.
- the amount of IgGs coupled to the gel can be determined by measuring the difference in optical density at 280 nm from the initial solution of IgGs and the direct eluate plus washes . 7.C - Adsorption and elution of the antigen
- a protein preparation of antigen in 50 mM Tris-HCl pH 8.0 2 mM EDTA for example the membrane fraction I or II (fraction C4 or C6 as obtained in Example 1 C and dissolved in zwittergent) is filtered through of a 0.45 ⁇ m membrane and is then deposited on the column equilibrated beforehand with 50 mM Tris-HCl pH 8.0 2 mM EDTA, at a flow rate of approximately 10 ml / hr. Then the column is washed with 20 vol. 50 mM Tris-HCl pH 8.0 2 mM EDTA. alternatively, the adsorption can be carried out in a bath; incubation is continued at 5 + 3 ° C overnight and with shaking.
- the gel is washed with 2 to 6 vol. 10 mM sodium phosphate buffer, pH 6.8.
- the antigen is eluted with 100 mM glycine buffer, pH 2.5.
- the eluate is collected in 3 ml fractions to which are added 150 ⁇ l of sodium phosphate buffer.
- Example 7 is repeated using the anti-fraction antiserum HpP6, in order to continue the purification of the fraction eluted between 0.26 and 0.31 M NaCl as described in Example 4.
- the fractions collected after elution and containing the protein are brought together in a single preparation; this is analyzed by electrophoresis on SDS Page 10% gel. A single band appears at 32 kDa.
- the biphasic medium comprises a solid phase consisting of 10 ml of Colombia agar (BioMérieux) supplemented with 6% fresh sheep blood and a liquid phase consisting of 3 ml of Trypticase soy broth (Difco) containing 20% fetal calf serum.
- the bottles are placed in a waterproof bag called “generbag” (BBL) and incubated with gentle rotary shaking at 37 ° C for 48 hours under microaerophilic conditions (8-10% C0 2 , 5-7% 0 2 and 85-87 % N 2 ) obtained by the System
- This 48 hour culture is used to re-inoculate vials containing biphasic medium.
- the initial absorbance of this culture at 600 nm must be between 0.15 and 0.2.
- the flasks are incubated under conditions identical to those described above.
- the bacterial suspension is transferred to a test tube.
- the absorbance of this culture is measured and it should be between 3.0 and 3.5 at 600nm.
- the appearance of the germs is checked under a microscope after staining with
- Example 5 An antiserum as obtained in Example 5 is filtered through a 0.45 ⁇ m membrane to remove the small aggregates if they exist before use.
- mice Groups of ten Swiss Webster mice aged 6 to 8 weeks (Taconic Labs. Germantown, NY) are immunized intragastrically with 1, 5, 25. 50 or 100 ⁇ g of the 54. 50 or 50 antigen 30 kDa purified by chromatography as described in Example 3; or 32 kDa antigen purified by chromatography as described in Example 4 or by immunoaffinity as described in Example 8; or 50 kDa antigen purified by immunoaffinity as described in Example 7 (preferred).
- the antigen is diluted in PBS or in PBS containing 0.24 M sodium bicarbonate.
- the antigen is supplemented with 5 or 10 ⁇ g of cholera toxin (CT) (Calbiochem, San Diego) or heat-labile toxin (LT) (Berna Products, Coral Gables FL).
- CT cholera toxin
- LT heat-labile toxin
- the mice are first anesthetized with isoflurane; then the dose is administered in a volume of approximately 0.5 ml using a cannula. Four doses are administered to each mouse 7-10 days apart. Two weeks after the last antigen administration, the mice are tested by a single dose of the H. pylori strain ORV2002 (1 ⁇ 10 7 of live bacteria in 200 ⁇ l of PBS; OD 550 of approximately 0.5) administered intragastrically. A group having received no dose of antigen and serving as a control is likewise tested.
- mice Two weeks after the test, the mice are sacrificed. The percentage of protection is determined either by measuring the urease activity or by evaluating the bacterial load by histology as described in Lee et al (supra) or directly by quantitative culture of H. pylori. Under these conditions, it is possible to observe for each of the proteins of 54, 50 30 and 32 kDa. a significant reduction in the infectious load in most mice immunized with 25 ⁇ g compared to the control group; this makes it possible to conclude that the antigens of 54, 50, 30 and 32 kDa of H. pylori are at least partially protective: the best results being obtained with the 32 kDa protein (100% protection) LIST OF SEQUENCES
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU72203/96A AU724013B2 (en) | 1995-10-04 | 1996-10-04 | Novel membrane proteins of helicobacter pylori |
JP9514037A JPH10511116A (ja) | 1995-10-04 | 1996-10-04 | ヘリコバクター・ピロリの新規膜タンパク |
NZ319640A NZ319640A (en) | 1995-10-04 | 1996-10-04 | protein obtained from the membrane of helicobacter pylori |
EP96933489A EP0793676A1 (fr) | 1995-10-04 | 1996-10-04 | Nouvelles proteines membranaires d'helicobacter pylori |
NO972532A NO972532L (no) | 1995-10-04 | 1997-06-03 | Nye membranproteiner av Helicobacter pylori |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9511890A FR2739622B1 (fr) | 1995-10-04 | 1995-10-04 | Nouvelles proteines membranaires d'helicobacter pylori |
FR95/11890 | 1995-10-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08849627 A-371-Of-International | 1998-02-19 | ||
US09/488,737 Continuation US20020151462A1 (en) | 1998-02-19 | 2000-01-20 | Helicobacter pylori membrane proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997012909A1 true WO1997012909A1 (fr) | 1997-04-10 |
Family
ID=9483402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/001552 WO1997012909A1 (fr) | 1995-10-04 | 1996-10-04 | Nouvelles proteines membranaires d'helicobacter pylori |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0793676A1 (fr) |
JP (1) | JPH10511116A (fr) |
CN (1) | CN1173877A (fr) |
AU (1) | AU724013B2 (fr) |
CA (1) | CA2206797A1 (fr) |
FR (1) | FR2739622B1 (fr) |
HU (1) | HUP9900498A3 (fr) |
NO (1) | NO972532L (fr) |
NZ (1) | NZ319640A (fr) |
WO (1) | WO1997012909A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004702A2 (fr) * | 1996-07-26 | 1998-02-05 | Chiron Behring Gmbh & Co. | Proteines, notamment proteines membranaires, d'helicobacter pylori, leur preparation et utilisation |
WO1998049314A2 (fr) * | 1997-04-25 | 1998-11-05 | Genelabs Technologies, Inc. | COMPOSITION ANTIGENIQUE ET METHODE DE DETECTION D'$i(HELICOBACTER PYLORI) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3869556B2 (ja) * | 1998-06-15 | 2007-01-17 | 勇 近藤 | ヘリコバクター・ピロリ由来抗原及びそれを用いたヘリコバクター・ピロリ感染の診断方法 |
JP5250812B2 (ja) * | 2006-04-27 | 2013-07-31 | 国立大学法人富山大学 | ヘリコバクター・ピロリ菌由来の新規抗原、抗原組成物およびピロリ菌抗体の検出方法。 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2669929A1 (fr) * | 1990-12-04 | 1992-06-05 | Quidel Corp | Composition d'antigenes, procede de detection de helicobacter pylori a l'aide de cette composition et necessaire la contenant. |
-
1995
- 1995-10-04 FR FR9511890A patent/FR2739622B1/fr not_active Expired - Fee Related
-
1996
- 1996-10-04 JP JP9514037A patent/JPH10511116A/ja not_active Withdrawn
- 1996-10-04 EP EP96933489A patent/EP0793676A1/fr not_active Withdrawn
- 1996-10-04 AU AU72203/96A patent/AU724013B2/en not_active Ceased
- 1996-10-04 CN CN96191777A patent/CN1173877A/zh active Pending
- 1996-10-04 NZ NZ319640A patent/NZ319640A/en unknown
- 1996-10-04 WO PCT/FR1996/001552 patent/WO1997012909A1/fr not_active Application Discontinuation
- 1996-10-04 CA CA002206797A patent/CA2206797A1/fr not_active Abandoned
- 1996-10-04 HU HU9900498A patent/HUP9900498A3/hu unknown
-
1997
- 1997-06-03 NO NO972532A patent/NO972532L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2669929A1 (fr) * | 1990-12-04 | 1992-06-05 | Quidel Corp | Composition d'antigenes, procede de detection de helicobacter pylori a l'aide de cette composition et necessaire la contenant. |
Non-Patent Citations (6)
Title |
---|
C.J. LUKE ET AL.: "IDENTIFICATION OF FLAGELLAR AND ASSOCIATED POLYPEPTIDES OF HELICOBACTER (FORMERLY CAAMPYLOBACTER) PYLORI.", FEMS MICROBIOLOGY LETTERS, vol. 71, 1990, AMSTERDAM, NL, pages 225 - 230, XP002003033 * |
M.A. TUFANO ET AL.: "IMMUNOBIOLOGICAL ACTIVITIES OF HELICOBACTER PYLORI PORINS.", INFECTION AND IMMUNITY, vol. 62, no. 4, April 1994 (1994-04-01), WASHINGTON US, pages 1392 - 1399, XP002003747 * |
M.M. EXNER ET AL.: "ISOLATION AND CHARACTERIZATION OF A FAMILY OF PORIN PROTEINS FROM HELICOBACTER PYLORI.", INFECTION AND IMMUNITY, vol. 63, no. 4, April 1995 (1995-04-01), WASHINGTON US, pages 1567 - 1572, XP002003585 * |
P. DOIG ET AL.: "IDENTIFICATION OF SURFACE- EXPOSED OUTER MEMBRANE ANTIGENS OF HELICOBACTER PYLORI.", INFECTION AND IMMUNITY, vol. 62, no. 10, October 1994 (1994-10-01), WASHINGTON US, pages 4526 - 4533, XP002003746 * |
P. DOIG ET AL.: "ISOLATION AND CHARACTERIZATION OF A CONSERVED PORIN PROTEIN FROM HELICOBACTER PYLORI.", JOURNAL OF BACTERIOLOGY, vol. 177, no. 19, October 1995 (1995-10-01), WASHINGTON, D.C., US, pages 5447 - 5452, XP000570478 * |
T.U. WESTBLOM ET AL.: "CATALASE NEGATIVE MUTANTS OF HELICOBACTER PYLORI.", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol. 11, no. 6, June 1992 (1992-06-01), WIESBADEN, DE, pages 522 - 526, XP002003748 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004702A2 (fr) * | 1996-07-26 | 1998-02-05 | Chiron Behring Gmbh & Co. | Proteines, notamment proteines membranaires, d'helicobacter pylori, leur preparation et utilisation |
WO1998004702A3 (fr) * | 1996-07-26 | 1998-04-23 | Chiron Behring Gmbh & Co | Proteines, notamment proteines membranaires, d'helicobacter pylori, leur preparation et utilisation |
WO1998049314A2 (fr) * | 1997-04-25 | 1998-11-05 | Genelabs Technologies, Inc. | COMPOSITION ANTIGENIQUE ET METHODE DE DETECTION D'$i(HELICOBACTER PYLORI) |
WO1998049314A3 (fr) * | 1997-04-25 | 1999-01-14 | Genelabs Tech Inc | COMPOSITION ANTIGENIQUE ET METHODE DE DETECTION D'$i(HELICOBACTER PYLORI) |
Also Published As
Publication number | Publication date |
---|---|
AU7220396A (en) | 1997-04-28 |
HUP9900498A3 (en) | 2001-03-28 |
EP0793676A1 (fr) | 1997-09-10 |
AU724013B2 (en) | 2000-09-07 |
NO972532L (no) | 1997-07-30 |
CA2206797A1 (fr) | 1997-04-10 |
NZ319640A (en) | 2000-02-28 |
FR2739622B1 (fr) | 1997-12-05 |
HUP9900498A2 (hu) | 1999-06-28 |
CN1173877A (zh) | 1998-02-18 |
JPH10511116A (ja) | 1998-10-27 |
NO972532D0 (no) | 1997-06-03 |
FR2739622A1 (fr) | 1997-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cover et al. | Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity | |
US6054132A (en) | Purified vacuolating toxin from Helicobacter pylori and methods to use same | |
EP0771214B1 (fr) | Traitement et prevention d'infections causees par les bacteries du genre helicobacter | |
CZ357397A3 (cs) | Antigeny Helicobacter pylori a vakcinační kompozice | |
JPH11504633A (ja) | 多量体の組換えウレアーゼワクチン | |
JP4368944B2 (ja) | 防御用ヘリコバクター抗原 | |
Jolley et al. | Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci | |
US20020151462A1 (en) | Helicobacter pylori membrane proteins | |
WO1997012908A1 (fr) | NOUVELLE PROTEINE MEMBRANAIRE p76 D'HELICOBACTER PYLORI | |
WO1997012909A1 (fr) | Nouvelles proteines membranaires d'helicobacter pylori | |
RU2186582C2 (ru) | Способ выделения и очистки белка внешней мембраны moraxella catarrhalis, штамм м.catarrhalis для получения белка cd, изолированный и очищенный неденатурированный белок cd внешней мембраны м.catarrhalis и иммуногенная композиция, содержащая белок cd внешней мембраны м.сatarrhalis | |
EP1475441B1 (fr) | Acides nucléiques et polypeptides spécifiques des souches pathogènes du genre Neisseria | |
EP0090660A2 (fr) | Vaccin anti-gonococcique | |
FR2633309A1 (fr) | Sequence d'adn codant pour la proteine p30 de toxoplasma gondii, produits d'expression de cette sequence, leurs procedes d'obtention et leurs applications | |
RU2335505C2 (ru) | Белок nmb0928 и его применение в фармацевтических композициях | |
FR2748478A1 (fr) | Nouvelle proteine membranaire d'helicobacter pylori | |
MXPA97004109A (es) | Nuevas proteinas de membrana helicobacter pylori | |
MXPA97004110A (es) | Nueva proteina de membrana helicobacter pylori p76 | |
AU702878B2 (en) | Treatment and prevention of helicobacter infection | |
FR2748477A1 (fr) | Nouvelle proteine membranaire d'helicobacter pylori | |
RU2336900C2 (ru) | Белок nmb1125 и его применение в фармацевтических композициях | |
Pal et al. | Electrophoretic mobility and immune response of outer membrane proteins of Vibrio cholerae O139 | |
Borrow et al. | The immune response to a meningococcal 200 kDa surface exposed protein following carriage and disease | |
EP2558485A1 (fr) | Antigenes polypeptidiques de trichinella, et leurs applications | |
FR2930646A1 (fr) | Detection, in vitro, d'anticorps produits a la suite d'une infection a legionella pneumophila |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96191777.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN HU JP MX NO NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 319640 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2206797 Country of ref document: CA Ref document number: 2206797 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/004109 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1997 849627 Country of ref document: US Date of ref document: 19970604 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996933489 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996933489 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996933489 Country of ref document: EP |